Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment

Anastasia Nijnik, Laurence Madera, Shuhua Ma, Matthew Waldbrook, Melissa R. Elliott, Donna M. Easton, Matthew L. Mayer, Sarah C. Mullaly, Jason Kindrachuk, Havard Jenssen, Robert Hancock

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

With the rapid rise in the incidence of multidrug resistant infections, there is substantial interest in host defense peptides as templates for production of new antimicrobial therapeutics. Natural peptides are multifunctional mediators of the innate immune response, with some direct antimicrobial activity and diverse immunomodulatory properties. We have previously developed an innate defense regulator (IDR) 1, with protective activity against bacterial infection mediated entirely through its effects on the immunity of the host, as a novel approach to anti-infective therapy. In this study, an immunomodulatory peptide IDR-1002 was selected from a library of bactenecin derivatives based on its substantially more potent ability to induce chemokines in human PBMCs. The enhanced chemokine induction activity of the peptide in vitro correlated with stronger protective activity in vivo in the Staphylococcus aureus-invasive infection model, with a >5-fold reduction in the protective dose in direct comparison with IDR-1. IDR-1002 also afforded protection against the Gram-negative bacterial pathogen Escherichia coli. Chemokine induction by IDR-1002 was found to be mediated through a Gi-coupled receptor and the PI3K, NF-κB, and MAPK signaling pathways. The protective activity of the peptide was associated with in vivo augmentation of chemokine production and recruitment of neutrophils and monocytes to the site of infection. These results highlight the importance of the chemokine induction activity of host defense peptides and demonstrate that the optimization of the ex vivo chemokine-induction properties of peptides is a promising method for the rational development of immunomodulatory IDR peptides with enhanced anti-infective activity.

LanguageEnglish
Pages2539-2550
Number of pages12
JournalJournal of Immunology
Volume184
Issue number5
DOIs
Publication statusPublished - 1 Mar 2010
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Nijnik, Anastasia ; Madera, Laurence ; Ma, Shuhua ; Waldbrook, Matthew ; Elliott, Melissa R. ; Easton, Donna M. ; Mayer, Matthew L. ; Mullaly, Sarah C. ; Kindrachuk, Jason ; Jenssen, Havard ; Hancock, Robert. / Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. In: Journal of Immunology. 2010 ; Vol. 184, No. 5. pp. 2539-2550.
@article{fc6831f0207d4961a4f43455f98d0ede,
title = "Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment",
abstract = "With the rapid rise in the incidence of multidrug resistant infections, there is substantial interest in host defense peptides as templates for production of new antimicrobial therapeutics. Natural peptides are multifunctional mediators of the innate immune response, with some direct antimicrobial activity and diverse immunomodulatory properties. We have previously developed an innate defense regulator (IDR) 1, with protective activity against bacterial infection mediated entirely through its effects on the immunity of the host, as a novel approach to anti-infective therapy. In this study, an immunomodulatory peptide IDR-1002 was selected from a library of bactenecin derivatives based on its substantially more potent ability to induce chemokines in human PBMCs. The enhanced chemokine induction activity of the peptide in vitro correlated with stronger protective activity in vivo in the Staphylococcus aureus-invasive infection model, with a >5-fold reduction in the protective dose in direct comparison with IDR-1. IDR-1002 also afforded protection against the Gram-negative bacterial pathogen Escherichia coli. Chemokine induction by IDR-1002 was found to be mediated through a Gi-coupled receptor and the PI3K, NF-κB, and MAPK signaling pathways. The protective activity of the peptide was associated with in vivo augmentation of chemokine production and recruitment of neutrophils and monocytes to the site of infection. These results highlight the importance of the chemokine induction activity of host defense peptides and demonstrate that the optimization of the ex vivo chemokine-induction properties of peptides is a promising method for the rational development of immunomodulatory IDR peptides with enhanced anti-infective activity.",
author = "Anastasia Nijnik and Laurence Madera and Shuhua Ma and Matthew Waldbrook and Elliott, {Melissa R.} and Easton, {Donna M.} and Mayer, {Matthew L.} and Mullaly, {Sarah C.} and Jason Kindrachuk and Havard Jenssen and Robert Hancock",
year = "2010",
month = "3",
day = "1",
doi = "10.4049/jimmunol.0901813",
language = "English",
volume = "184",
pages = "2539--2550",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

Nijnik, A, Madera, L, Ma, S, Waldbrook, M, Elliott, MR, Easton, DM, Mayer, ML, Mullaly, SC, Kindrachuk, J, Jenssen, H & Hancock, R 2010, 'Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment', Journal of Immunology, vol. 184, no. 5, pp. 2539-2550. https://doi.org/10.4049/jimmunol.0901813

Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. / Nijnik, Anastasia; Madera, Laurence; Ma, Shuhua; Waldbrook, Matthew; Elliott, Melissa R.; Easton, Donna M.; Mayer, Matthew L.; Mullaly, Sarah C.; Kindrachuk, Jason; Jenssen, Havard; Hancock, Robert.

In: Journal of Immunology, Vol. 184, No. 5, 01.03.2010, p. 2539-2550.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment

AU - Nijnik, Anastasia

AU - Madera, Laurence

AU - Ma, Shuhua

AU - Waldbrook, Matthew

AU - Elliott, Melissa R.

AU - Easton, Donna M.

AU - Mayer, Matthew L.

AU - Mullaly, Sarah C.

AU - Kindrachuk, Jason

AU - Jenssen, Havard

AU - Hancock, Robert

PY - 2010/3/1

Y1 - 2010/3/1

N2 - With the rapid rise in the incidence of multidrug resistant infections, there is substantial interest in host defense peptides as templates for production of new antimicrobial therapeutics. Natural peptides are multifunctional mediators of the innate immune response, with some direct antimicrobial activity and diverse immunomodulatory properties. We have previously developed an innate defense regulator (IDR) 1, with protective activity against bacterial infection mediated entirely through its effects on the immunity of the host, as a novel approach to anti-infective therapy. In this study, an immunomodulatory peptide IDR-1002 was selected from a library of bactenecin derivatives based on its substantially more potent ability to induce chemokines in human PBMCs. The enhanced chemokine induction activity of the peptide in vitro correlated with stronger protective activity in vivo in the Staphylococcus aureus-invasive infection model, with a >5-fold reduction in the protective dose in direct comparison with IDR-1. IDR-1002 also afforded protection against the Gram-negative bacterial pathogen Escherichia coli. Chemokine induction by IDR-1002 was found to be mediated through a Gi-coupled receptor and the PI3K, NF-κB, and MAPK signaling pathways. The protective activity of the peptide was associated with in vivo augmentation of chemokine production and recruitment of neutrophils and monocytes to the site of infection. These results highlight the importance of the chemokine induction activity of host defense peptides and demonstrate that the optimization of the ex vivo chemokine-induction properties of peptides is a promising method for the rational development of immunomodulatory IDR peptides with enhanced anti-infective activity.

AB - With the rapid rise in the incidence of multidrug resistant infections, there is substantial interest in host defense peptides as templates for production of new antimicrobial therapeutics. Natural peptides are multifunctional mediators of the innate immune response, with some direct antimicrobial activity and diverse immunomodulatory properties. We have previously developed an innate defense regulator (IDR) 1, with protective activity against bacterial infection mediated entirely through its effects on the immunity of the host, as a novel approach to anti-infective therapy. In this study, an immunomodulatory peptide IDR-1002 was selected from a library of bactenecin derivatives based on its substantially more potent ability to induce chemokines in human PBMCs. The enhanced chemokine induction activity of the peptide in vitro correlated with stronger protective activity in vivo in the Staphylococcus aureus-invasive infection model, with a >5-fold reduction in the protective dose in direct comparison with IDR-1. IDR-1002 also afforded protection against the Gram-negative bacterial pathogen Escherichia coli. Chemokine induction by IDR-1002 was found to be mediated through a Gi-coupled receptor and the PI3K, NF-κB, and MAPK signaling pathways. The protective activity of the peptide was associated with in vivo augmentation of chemokine production and recruitment of neutrophils and monocytes to the site of infection. These results highlight the importance of the chemokine induction activity of host defense peptides and demonstrate that the optimization of the ex vivo chemokine-induction properties of peptides is a promising method for the rational development of immunomodulatory IDR peptides with enhanced anti-infective activity.

UR - http://www.scopus.com/inward/record.url?scp=77951908013&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0901813

DO - 10.4049/jimmunol.0901813

M3 - Article

VL - 184

SP - 2539

EP - 2550

JO - Journal of Immunology

T2 - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -